Showing results (121-130 of 177) with videos related to
Sort By:
Pageof 18
Human Mutation|August 25, 2019
Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinomaLiying Zhang, Michael F Walsh, Sowmya Jairam, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian CancerBritta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing PanelsZsofia K Stadler, Francesca Battaglin, Sumit Middha, et al.Journal of the National Cancer Institute|March 3, 2020
Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast CancerAnne S Reiner, Mark E Robson, Lene Mellemkjær, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 3, 2024
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factorsBrent Mabey, Elisha Hughes, Matthew Kucera, et al.NPJ Breast Cancer|November 10, 2017
Erratum: Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer riskThomas P Slavin, Kara N Maxwell, Jenna Lilyquist, et al.NPJ Breast Cancer|June 27, 2017
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer riskThomas P Slavin, Kara N Maxwell, Jenna Lilyquist, et al.Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesNadine M Tung, Mark E Robson, Steffen Ventz, et al.Pageof 18